Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Neuroscience Right
  3. Emgality (galcanezumab-gnlm) injection Right
  4. What are the recommended doses of EMGALITY® (galcanezumab-gnlm) and how is it administered?
Search Emgality (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Emgality ® (galcanezumab-gnlm) injection

100 mg/mL, 120 mg/mL

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What are the recommended doses of EMGALITY® (galcanezumab-gnlm) and how is it administered?

The migraine prevention dose is 120 mg once monthly, with a 240 mg loading dose as the initial dose. The episodic cluster headache dose is 300 mg at the onset of the cluster period, and then monthly until the end of the cluster period.

US_cFAQ_GLC019_DOSAGE_ADMINISTRATION
US_cFAQ_GLC019_DOSAGE_ADMINISTRATION
en-US

Migraine Prevention Dosing

The recommended dose is 120-mg injected subcutaneously once monthly, following an initial 240-mg loading loading dose (administered as 2 consecutive injections of 120 mg each).1

Episodic Cluster Headache Dosing

The recommended dose is 300 mg, 3 consecutive injections of 100 mg each, injected subcutaneously monthly throughout a cluster period.1

Method of Administration

Galcanezumab is for subcutaneous administration.1 A patient may self-inject by following the instructions for use.

Sites for injection include the

  • abdomen
  • thigh
  • back of the upper arm, and
  • buttocks.1

Enclosed Prescribing Information

EMGALITY® (galcanezumab-gnlm) injection, for subcutaneous use, Lilly

References

1Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.

Date of Last Review: January 24, 2022

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly